Hubbard: Bleeding and Clotting DSA Flashcards

1
Q

__________ = most important predictor of bleeding

risk.

A

History of bleeding risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

________= hallmark of moderate and severe factor 8 and 9 deficiency

A

Spontaneous hemarthroses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Disorders due to ABNL platelets vs coagulation facts cause WHAT findings

A
  1. ABNL platelets = Mucosal/skin bleeding => peteechiae

2. ABNL coagulation factors = JOINT bleeding, deep tissue bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does bleeding due to clotting factor abnormalities differ from those seen with platelet deficiencies?

A
  1. Spontaneous petechiae/purpura = uncommon
  2. Bleeding manifests as large excxymoses or hematomas after injury or prolonged bleeding after laceration/surgery.
  3. Often occurs into the GI/GU tracts and into weight-bearing joints (hemarthrosis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

_______ = suggestive of underlying
platelet disorders or Von Willebrand disease (VWD), also called disorders of primary hemostasis or platelet plug formation.

A

Mucosal bleeding symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Bleeding symptoms that appear to be more common in patients with
bleeding disorders include …

A
  1. Prolonged bleeding with surgery
  2. Dental procedures and extractions, and/or trauma
  3. Heavy menstrual
    bleeding (HMB)
  4. Postpartum hemorrhage (PPH)
  5. Large bruises (often described with lumps).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
\_\_\_\_\_\_  = MC symptom in hereditary
hemorrhagic telangiectasia (HHT) and in boys with VWD
A

Epistaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Bleeding with eruption of primary teeth = common in _________

A

Kids with severe bleeding disorders (moderate - severe hemophilia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Heavy menstrual bleeding = loss of ______ of blood per cycle, based on the quantity of blood loss required to produce iron-deficiency anemia

A

> 80 mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Complaint of heavy menses is subjective and poorly correlates with excessive
blood loss. Predictors of HMB include bleeding resulting in: (4)

A
  1. Iron-deficiency anemia
  2. Need for blood transfusion
  3. Passage of clots >1 in. in diameter,
  4. Changing a pad or tampon more than hourly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

HMB is a common symptom in women with underlying

bleeding disorders and is reported in the majority of women with

A
  1. VWD
  2. Factor XI deficiency, and symptomatic carriers
    of hemophilia.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

_________

has been associated with angiodysplasia of the bowel and GI bleeding.

A

VWD, particularly types 2 and 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Hemarthroses and spontaneous muscle hematomas are

characteristic of __________

A

Moderate - severe congenital factor 8 or 9

deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Muscle and soft tissue bleeds are also common in ______

A

factor 8 deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Life-threatening sites

of bleeding include bleeding into the

A
  1. Oropharynx
  2. CNS
  3. Retroperitoneum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

_________ bleeding is the

major cause of bleeding-related deaths in patients with severe congenital factor deficiencies

A

CNS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What medications and dietary supplements have pro-hemorrhagic effects

A
  1. ASA and NSAIDS that inhibit COX-1 => impair primary hemostasis
  2. ADP P2Y12 inhibitors (-grel drugs) = inhibit platelet aggregation & have higher risk of bleeding
  3. Fish oil/omega3 FA = INC PGI3, which impair platelet function
  4. Vitamin E = inhibits PKC-mediated platelet aggregation and NO production
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

UNDERLYING SYSTEMIC

DISEASES THAT may be present with bruising/mucosal bleeding

A
  1. Liver disease
  2. Severe renal impairment
  3. Hypothyroidism
  4. Paraproteineimias
  5. Amyloidosis
  6. Conditions causing BM failure.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What factors are dependent on Vit. K?

Vitamin K deficiency results in?

A

Factors 2, 7, 9, and 10, as well as protein C and protein S

-Bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

NL blood platelet count is _______

A

150,000–450,000/μL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What platelet count does spontaneous bleeding occur?

A

<10,000–20,000/μL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

At what platelet count can most surgical procedures be performed at?

A

50,000/μL, but preferably ~80,000/μL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the major RF for arterial vs venous thrombosis?

A
  1. Arterial = atherosclerosis
  2. Venous = immobility, surgery, underlying medical conditions like hormonal therapy, obesity and genetic predispositions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Most important point in a history related to venous

thrombosis is determining whether the thrombotic event was …

A

Idiopathic (no clear precipitating factor) or

was a precipitated event.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

In patients without underlying
malignancy, ___________ = strongest predictor of
recurrence of VT

A

Having an idiopathic event

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Routine pre-op and pre-procedure testing, an abnormal prothrombin time (PT) may detect…

A
  1. Liver disease

2. Vitamin K deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

The most commonly used screening tests are the _________

A
  1. PT
  2. aPTT
  3. Platelet count
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

INR is used for what?

A
  1. Assess stable anticoagulation due to reduction of vitamin K–dependent co-ag factors;
  2. Liver disease.

Allows comparison between laboratories.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Mixing studies are used for what?

A

Evaluate a prolonged aPTT or, less commonly PT, to distinguish between a factor deficiency and an
inhibitor.

If isolated factor deficiencies => the aPTT will correct. with mixing and stay corrected with incubation. With aPTT
prolongation due to a lupus anticoagulant, the mixing and
incubation will show no correction. In acquired neutralizing factor
antibodies, notably an acquired factor VIII inhibitor, the initial assay
may or may not correct immediately after mixing but will prolong
or remain prolonged with incubation at 37°C.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

How is a mixing study performed?

A

NL plasma and patient plasma are mixed
in a 1:1 ratio => determine aPTT or PT .

If isolated factor deficiencies => aPTT will correct.

aPTT
prolongation due to a lupus anticoagulant => aPTT will not correct.

In acquired neutralizing factor
Ab, notably an acquired factor 8-inhibitor => the initial assay may or may not correct immediately after mixing but will prolong
or remain prolonged with incubation at 37°C.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

When are specific factor assays REQUIRED?

How are they performed?

A

When bleeding is severe

To perform: a modification of
the mixing study: mix patient’s plasma with plasma deficient in the factor being studied.

32
Q

How can we test for Anti-phospholipid AB (cardiolipin Ab or B2-microglobulin)?

A

ELISA

33
Q

What are dRVVT and TTI?

A

drVVT = dilute Russel viper venom test

TTI = tissue thromboplastin inhibition

Modifications of standard
tests with the phospholipid reagent decreased, thus increasing the sensitivity to Ab that interfere with the phospholipid
component. The tests, however, are not specific for lupus anticoagulants, because factor deficiencies or other inhibitors will also result in prolongation.

34
Q

Documentation of a lupus

anticoagulant requires

A

Prolongation of a phospholipid dependent
coagulation test + lack of correction when
mixed with normal plasma and correction with the addition of
activated platelet membranes or certain phospholipids

35
Q

What is thrombin time and reptilase time and when are they used?

A

Measure conversion of fibrinogen => fibrin

Prolonged when the fibrinogen level
is low (usually <80–100 mg/dL) or qualitatively abnormal, as seen in inherited/acquired dysfibrongenemias and/or when fibrin/fibrinogen products interfere.
36
Q

___________ time is prolonged in the presence of heparin.

A

Thrombin/reptilase time

37
Q

How are the following factors affected in thrombophilia (clotting disorders)?

  1. Antithrombin
  2. Protein C/S
  3. Antiphospholipid AB
A
  1. Decreased (also decreased by heparin)
  2. Increased (decreased by Warfarin)
  3. AP AB (positive)
38
Q

Thrombophila evaluations

How is it done?
Why?
When?

A

How = molecular diagnostics, immunologic and functional assays.

Why = assess need to extend anti-coagulation studies

When = in a steady state, remote from acute event. Stop warfarin after the initial 3-6 months of treatment and testing can be performed at least 3 weeks later.

39
Q

Screening assays that are sensitive and specific for platelet function (platelet disorders and VWD)

A
  1. PFA-100 and similar instruments that measure platelet-dependent coagulation.

However, don’t use to predict bleeding risk or monitor response to therapy.

40
Q

Venous stasis is usually due to what?

A
  1. Chronic insufficiency of the venous system (varicose veins)
  2. Inflammatory damage to veins (post-phlebitic syndrome)
41
Q

How do patients with venous stasis typically present?

A
  1. Progressive LE edema, with achy pain in legs that worsens with standing
  2. Shiny, atrophic skin
  3. Telangiectasies
  4. Varicose veins
42
Q

1st line of treatment for venous stasis

A

External compression + behavior modification (no prolonged periods of standing + leg elevation)

43
Q

Treatment ulcers due to chronic venous stasis

A

Unna boots = specialized compressive dressing treated with agents to decrease edema + promote healing. However, must be put on by medical professional.

44
Q

What are the 2 manifestations of venous thromboembolism (VTE)?

A
  1. DVT

2. PE

45
Q

The syndrome of DVT includes thrombosis in which 2 areas?

A
  1. Vein in proximal leg

2. Large veins in the UE

46
Q

Why is the incidence of DVT of the upper extremities rising in incidence?

A

Secondary to ↑ use of indwelling venous catheters

47
Q

How do patients with a LE DVT usually present?

A

Affected limb:

  1. Erythema
  2. Swelling
  3. Tenderness
48
Q

The initial and most important step in evaluating a possible DVT is what?

A

Determine the clinical likelihood of disease, so we can figure out the proper testing.

49
Q

Initial assessment of DVT =

A

Wells score

50
Q

Testing in patients with a low clinical

likelihood of DVT

A

D-dimer: Low clinical probability + (-) D-dimer => rules out DVT

51
Q

Testing in patients with a (+) D-dimer or if clinical likelihood of DVT is high (+ Wells)

A

Duplex Ultrasound: excellent sensitivity and specificity for DVT

52
Q

Gold standard test for DVT

A

Venography, but rarely used.

53
Q

Who should receive prophylaxis for DVT/PE?

A
  1. Known thrombophilic condition

2. All hospitalized patients with VTE RF and no CI.

54
Q

What is the most effective treatment for prevention of VTE in hospitalized pt’s with risk factors?

A

Pharmacologic prophylaxis

55
Q

What is a pro and con of using D-dimer in the assessment of DVT/PE?

A
  • Pro = negative test makes DVT unlikely; simple to perform

- Con = positive test is not diagnostic of DVT; other conditions can elevate D-dimer

56
Q

All patients with an established DVT and no CI should undergo _______.

A

Immediate anticoagulation: IV unfractionated heparin or LMW heparin

57
Q

Which agent is used most often for longer-term anticoagulation in pt with established DVT; describe how it’s administered and the guidelines that need to be followed?

A
  • Warfarin

- Typically started w/ heparin and both used for minimum 5 days until INR = 2-3 for 2 measurements taken 24 hrs apart

58
Q

What are some pros and cons of the newer anticoagulant agents, dabigatran, rivaroxaban, apixaban, and edoxaban?

A
  • Oral, rapid onset, do not require monitoring or overlap w/ heparin; minimal interactions with foods and other meds
  • Most cannot be used in pt’s w/ significant kidney failure
59
Q

Once a patient with established DVT is on stable anticoagulation they should be treated for a minimum of how long?

A

3 months

60
Q

If there are strong CI to anticoagulant therapy in pts with established DVT, what treatment option exists; what are some downfalls to this treatment?

A
  • Inferior vena cava filter

- Will ↓ likelihood of PE in short-term, but they may actually ↑ the long-term risk of recurrent DVT

61
Q

Should patients at risk for VTE be screened for DVT or PE (ex. via D-dimer)?

A

No: insensitive and does not improve clinical outcomes

62
Q

Most common symptoms of PE

A
  1. Dyspnea
  2. Pleuritic chest pain
  3. Cough
  4. Hemoptysis
  5. Tachypnea, crackles, tachycardia, and
    accentuated pulmonic component of S2
63
Q

In clinically stable patients (eg, outpatients without hemodynamic compromise) with a low probability of PE, what can effectively r/o a PE?

A

NL D-dimer

64
Q

What is the indication for using D-dimer in pt’s with a higher probability of PE or clinical instability?

A

D-dimer testing should NOT be used to confirm or exclude the diagnosis.

Further testing is indicated.

65
Q

Initial imaging test for PE =

A
  1. Contrast-enhanced CT (also called
    CT angiography)***
  2. Ventilation-perfusion (V/Q) scanning
66
Q

What is considered the gold standard screening modality for DVT/PE in intermediate cases; what are some pros and cons of using it?

A
  • CT pulmonary angiography (CT angiography)
  • Pros: high sensitivity and specificity; accurate anatomy assessment
  • Cons: requires contrast (allergies, AKI), expensive, radiation exposure, and may miss small peripheral clots
67
Q

What are the pros and cons of using ventilation/perfusion scans in the evaluation of DVT/PE?

A
  • Pros: high sensitivity + inexpensive

- Cons: low specificity + may not demonstrate small sub-segmental defects

68
Q

A totally normal finding using which imaging modality is the only one that can exclude PE?

A

V/Q scan

69
Q

What would be the imaging modality of choice to use in a patient with renal failure or someone who is obese for initial assessment of PE?

A

V/Q scan

70
Q

How are MOST patients with a PE managed?

A

Hospital, until stable with supportive care, including treatment of hypoxia and management of hemodynamic instability.

71
Q

How should patients with circulatory shock due to PE, those with
acute embolism and pulmonary HTN or right ventricular
dysfunction but without arterial hypotension or shock be treated?

A

Thrombolytic therapy (clot lysis)

72
Q

Treatment of patient who is

unstable and thrombolytic therapy is CI or if drug therapy has been unsuccessful.

A

Surgical embolectomy

73
Q

Prevention of PE with an IVC filter is indicated when?

A
  1. Failure of medical therapy (evidence of PE despite adequate
    anticoagulation)
  2. CI to anticoagulant therapy
    due to unacceptably high bleeding risk
74
Q

Once a patient is on stable anticoagulation with PE, how long should therapy be continued?

A

For a duration based on the individual risk factor profile

75
Q

RF for thrombosis

A
  1. Old age (>80YO)
  2. Surgery
  3. Immobilization
  4. PG
  5. Hospitilized prior to DVT
  6. Smoking